Please login to the form below

Not currently logged in
Email:
Password:

Sosei

This page shows the latest Sosei news and features for those working in and with pharma, biotech and healthcare.

Dr Fiona Marshall heads up MSD's new UK research facility

Dr Fiona Marshall heads up MSD's new UK research facility

Dr Marshall joins the new venture from Sosei Group Corporation, where she was executive vice president and chief scientific officer, and she also co-founded Heptares Therapeutics, a biotechnology company, which ... was acquired by Sosei in 2015.

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition– asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐ oncology small molecule and

  • Pharma deals in February 2015 Pharma deals in February 2015

    It came as no surprise therefore to learn of Sosei's acquisition of this UK biotech jewel with an upfront payment of $180m in cash and up to $220m in milestones.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints CFO Sosei appoints CFO

    Sosei appoints CFO. Andrew Oakley joins the Tokyo-based pharma firm. Andrew Oakley has joined Tokyo-based pharmaceutical firm Sosei as chief financial officer, succeeding Hidetoshi Torami. ... Peter Bains, chief executive officer of Sosei, said: “

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    Sosei appoints chief operating officer. Peter Bains also takes on the role of representative executive officer. ... Tokyo, Japan-based Sosei has appointed Peter Bains as its chief operating officer and representative executive officer.

  • Dr David Chiswell joins Kymab Dr David Chiswell joins Kymab

    He brings over 30 years of biotechnology expertise to the firm, having held senior management positions at a number of pharmaceutical companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics